The current status of screening for gastric cancer-risk (gastritis A, B, C, D) method using combined assay for serum anti-
Helicobacter pylori (
Hp) IgG antibody and serum pepsinogen (PG) levels, “ABC method”, was reviewed and the latest results of our ongoing trial are reported. It was performed using the following strategy: Subjects were classified into 1 of 4 risk groups based on the results of the two serologic tests, anti-
Hp IgG antibody titers and the PG I and II levels: Group A [
Hp(−)PG(−)], infection-free subjects; Group B [
Hp(+)PG(−)], chronic atrophic gastritis (CAG) free or mild; Group C [
Hp(+)PG(+)], CAG; Group D [
Hp(−)PG(+)]), severe CAG with extensive intestinal metaplasia. Continuous endoscopic follow-up examinations are required to detect early stages of gastric cancer. Asymptomatic Group A, which accounts for 50–80% of all the subjects may be excluded from the secondary endoscopic examination, from the viewpoint of efficiency.
Hp-infected subjects should be administered eradication treatment aimed at the prevention of gastric cancer.
(Communicated by Takashi SUGIMURA, M.J.A.)
抄録全体を表示